Müller Johannes, Plöchl Walter, Mühlbacher Paul, Graf Alexandra, Stimpfl Thomas, Hamp Thomas
Division of General Anaesthesia and Intensive Care Medicine, Department of Anaesthesia, Intensive Care and Pain Medicine, Medical University of Vienna, Vienna, Austria.
Center for Medical Statistics, Informatics and Intelligent Systems, Institute for Medical Statistics, Medical University of Vienna, Vienna, Austria.
Front Med (Lausanne). 2022 May 3;9:883181. doi: 10.3389/fmed.2022.883181. eCollection 2022.
Pregabalin is commonly used perioperatively to reduce post-operative pain and opioid consumption and to prevent the development of chronic pain. It has been shown to reduce anesthetic consumption in balanced anesthesia, but studies investigating its effect on the minimum alveolar concentration (MAC) of volatile anesthetics are lacking. The aim of this study was to investigate the effect of two different doses of pregabalin on the MAC of sevoflurane.
In a randomized, double-blinded, placebo controlled clinical study, 75 patients were assigned to receive placebo, 300 mg pregabalin, or 150 mg pregabalin, as a capsule 1 h before anesthesia induction with sevoflurane only. After equilibration, the response to skin incision (movement vs. non-movement) was monitored. The MAC was assessed using an up- and down-titration method.
The MAC of sevoflurane was estimated as 2.16% (95% CI, 2.07-2.32%) in the placebo group, 1.44% (95% CI, 1.26-1.70%) in the 300 mg pregabalin group, and 1.81% (95% CI, 1.49-2.13%) in the 150 mg pregabalin group. We therefore report a 33% reduction in the MAC of sevoflurane in the 300 mg pregabalin group as compared to placebo. The MAC of the 150 mg pregabalin group was reduced by 16% as compared to placebo but was not statistically significant.
The administration of 300 mg pregabalin reduced the MAC of sevoflurane by 33%, while the administration of 150 mg pregabalin did not significantly reduce the MAC of sevoflurane. Pregabalin use led to a small reduction in post-operative pain levels but increased side effects in a dose-dependent manner.
围手术期常用普瑞巴林来减轻术后疼痛、减少阿片类药物用量并预防慢性疼痛的发生。研究表明,在平衡麻醉中普瑞巴林可减少麻醉药物用量,但关于其对挥发性麻醉药最低肺泡浓度(MAC)影响的研究较少。本研究旨在探讨两种不同剂量的普瑞巴林对七氟醚MAC的影响。
在一项随机、双盲、安慰剂对照的临床研究中,75例患者被分配接受安慰剂、300mg普瑞巴林或150mg普瑞巴林,于仅用七氟醚诱导麻醉前1小时以胶囊形式给药。平衡后,监测对皮肤切口的反应(活动与无活动)。采用上下滴定法评估MAC。
安慰剂组七氟醚的MAC估计为2.16%(95%CI,2.07 - 2.32%),300mg普瑞巴林组为1.44%(95%CI,1.26 - 1.70%),150mg普瑞巴林组为1.81%(95%CI,1.49 - 2.13%)。因此,我们报告300mg普瑞巴林组七氟醚的MAC与安慰剂组相比降低了33%。150mg普瑞巴林组的MAC与安慰剂组相比降低了16%,但无统计学意义。
给予300mg普瑞巴林可使七氟醚的MAC降低33%,而给予150mg普瑞巴林并未显著降低七氟醚的MAC。使用普瑞巴林可使术后疼痛水平略有降低,但副作用呈剂量依赖性增加。